KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Castle Biosciences (CSTL) Depreciation & Amortization (CF): 2018-2025

Historic Depreciation & Amortization (CF) for Castle Biosciences (CSTL) over the last 8 years, with Sep 2025 value amounting to $3.8 million.

  • Castle Biosciences' Depreciation & Amortization (CF) rose 7.77% to $3.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $42.8 million, marking a year-over-year increase of 217.86%. This contributed to the annual value of $16.0 million for FY2024, which is 29.74% up from last year.
  • According to the latest figures from Q3 2025, Castle Biosciences' Depreciation & Amortization (CF) is $3.8 million, which was up 11.78% from $3.4 million recorded in Q2 2025.
  • In the past 5 years, Castle Biosciences' Depreciation & Amortization (CF) registered a high of $29.8 million during Q1 2025, and its lowest value of $233,000 during Q1 2021.
  • Moreover, its 3-year median value for Depreciation & Amortization (CF) was $3.3 million (2024), whereas its average is $5.9 million.
  • Data for Castle Biosciences' Depreciation & Amortization (CF) shows a peak YoY soared of 823.18% (in 2022) over the last 5 years.
  • Quarterly analysis of 5 years shows Castle Biosciences' Depreciation & Amortization (CF) stood at $1.5 million in 2021, then soared by 95.80% to $2.8 million in 2022, then grew by 13.48% to $3.2 million in 2023, then spiked by 78.91% to $5.8 million in 2024, then grew by 7.77% to $3.8 million in 2025.
  • Its Depreciation & Amortization (CF) was $3.8 million in Q3 2025, compared to $3.4 million in Q2 2025 and $29.8 million in Q1 2025.